Glucotrack, a startup making an implantable glucose monitor, shared data from a first-in-human trial in June during the American Diabetes Association’s Scientific Sessions. The 10-person study, where patients were observed inpatient for four days and for a week after device removal, met safety and performance endpoints.
CEO Paul Goode said in an interview that the goal of the study was to show that the device and the procedure to implant it were safe.
No serious adverse events were reported during the study. For accuracy, the results showed a mean absolute relative difference of 7.7%, which would make the device competitive with CGMs on the market, although Goode cautioned that the data is very early and the results were not statistically significant. MARD is a measurement that compares blood glucose readings from a CGM to reference measurements, such as blood glucose from a fingerstick.